###begin article-title 0
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 57 64 57 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
Level and course of FEV1 in relation to polymorphisms in NFE2L2 and KEAP1 in the general population
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 357 363 357 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nfe2l2</italic>
###xml 574 575 574 575 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 374 378 <span type="species:ncbi:10090">mice</span>
###xml 387 394 <span type="species:ncbi:4097">tobacco</span>
The metabolism of xenobiotics plays an essential role in smoking related lung function loss and development of Chronic Obstructive Pulmonary Disease. Nuclear Factor Erythroid 2-Like 2 (NFE2L2 or NRF2) and its cytosolic repressor Kelch-like ECH-associated protein-1 (KEAP1) regulate transcription of enzymes involved in cellular detoxification processes and Nfe2l2-deficient mice develop tobacco-induced emphysema. We assessed the impact of Single Nucleotide Polymorphisms (SNPs) in both genes on the level and longitudinal course of Forced Expiratory Volume in 1 second (FEV1) in the general population.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 5 12 5 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 189 191 189 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 240 242 240 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 395 397 395 397 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Five NFE2L2 and three KEAP1 tagging SNPs were genotyped in the population-based Doetinchem cohort (n = 1,152) and the independent Vlagtwedde-Vlaardingen cohort (n = 1,390). On average 3 FEV1 measurements during 3 surveys, respectively 7 FEV1 measurements during 8 surveys were present. Linear Mixed Effect models were used to test cross-sectional and longitudinal genetic effects on repeated FEV1 measurements.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 93 95 93 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 157 164 157 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 195 197 195 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 320 326 320 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 329 336 329 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 349 351 349 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
In the Vlagtwedde-Vlaardingen cohort SNP rs11085735 in KEAP1 was associated with a higher FEV1 level (p = 0.02 for an additive effect), and SNP rs2364723 in NFE2L2 was associated with a lower FEV1 level (p = 0.06). The associations were even more significant in the pooled cohort analysis. No significant association of KEAP1 or NFE2L2 SNPs with FEV1 decline was observed.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 92 98 92 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 102 109 102 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 176 183 176 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 187 193 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 222 224 222 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 278 285 278 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 289 295 289 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 367 369 367 369 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
This is the first genetic study on variations in key antioxidant transcriptional regulators KEAP1 and NFE2L2 and lung function in a general population. It identified 2 SNPs in NFE2L2 and KEAP1 which affect the level of FEV1 in the general population. It additionally shows that NFE2L2 and KEAP1 variations are unlikely to play a role in the longitudinal course of FEV1 in the general population.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 562 563 562 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 564 565 564 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 757 758 757 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
The mortality and morbidity of Chronic Obstructive Pulmonary Disease (COPD) has been increasing over the past decades and the disease is a fundamental medical and economical problem in Western societies [1]. A genetic predisposition is thought to play a crucial role in the onset of COPD and the heritability of lung function loss that precedes COPD development has been clearly established [2,3]. Several polymorphisms have been identified in association with level of lung function, but subsequent studies have failed to replicate these reported associations [4,5]. So far, only a small subset of polymorphisms has been consistently replicated in their association with COPD development or lung function decline across independent studies or populations [6-11].
###end p 11
###begin p 12
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
Nuclear Factor (Erythroid-derived 2)-Like 2 (NFE2L2 or NRF2) regulates the transcription of numerous antioxidant enzymes in response to oxidant injury, via direct binding to the antioxidant responsive element in the target gene [12-15]. It therefore is a potent candidate gene for excess lung function loss and COPD development.
###end p 12
###begin p 13
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 276 283 276 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nfe2l2 </italic>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 408 414 408 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 418 425 418 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 702 708 702 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2</italic>
###xml 776 778 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 840 847 840 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 858 867 858 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 950 952 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1003 1010 1003 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 1013 1019 1013 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 292 296 <span type="species:ncbi:10090">mice</span>
###xml 331 338 <span type="species:ncbi:4097">tobacco</span>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
Kelch-like ECH-associated protein-1 (KEAP1) is a cytosolic repressor of NFE2L2. Oxidative stress causes disruption of the KEAP1-NFE2L2 complex, translocation of NFE2L2 to the nucleus and subsequent induction of the expression of antioxidant genes [16]. It has been shown that Nfe2l2 protects mice against elastase-induced [17] and tobacco-induced [18] emphysema. Additionally, the expression pattern of both KEAP1 and NFE2L2 is different in COPD patients as compared to healthy never- or former- smokers [19,20] and the expression of NFE2L2-regulated antioxidant genes is lower in COPD subjects than in non-diseased controls [21]. Three new polymorphisms have been discovered in the promoter region of NFE2L2, but these were not associated with COPD in a Japanese population [22]. One study showed that one of these polymorphisms decreases NFE2L2 expression in vitro and is associated with development of acute lung injury in a Caucasian population [23]. So far no studies have investigated the role of NFE2L2 or KEAP1 polymorphisms in relation to the longitudinal course of lung function in the general population.
###end p 13
###begin p 14
###xml 56 63 56 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 133 135 133 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Therefore, in the current study we investigated whether NFE2L2 or KEAP1 polymorphisms affect the level and longitudinal course of FEV1 (Forced Expiratory Volume in 1 second), both being important risks for COPD [24]. In order to assure consistency of results, we performed this study in two prospective and independent population-based cohorts.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Subjects
###end title 16
###begin p 17
###xml 43 45 43 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 155 157 155 157 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 394 396 394 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 577 579 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
Subjects from the Doetinchem cohort study [25], a prospective part of the MORGEN study [26], were included. A sub-sample (n = 1,152 subjects with 3,115 FEV1 measurements during 3 surveys: surveys 1993-1997 (n = 1,152), 1998-2002 (n = 1,152), and 2003-2007 (n = 811)), table 1) was randomly selected from the total cohort with spirometry tests and DNA available as described previously [27]. FEV1 was measured three times (maneuver performed with a heated pneumotachograph (Jaeger, Germany)) with 5-year intervals according to the European Respiratory Society (ERS) guidelines [28].
###end p 17
###begin p 18
Characteristics of Doetinchem cohort and Vlagtwedde-Vlaardingen cohort
###end p 18
###begin p 19
###xml 3 5 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
FEV1 = Forced Expiratory Volume in 1 second
###end p 19
###begin p 20
SD = Standard Deviation
###end p 20
###begin p 21
###xml 80 82 80 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 119 120 119 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 208 210 208 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
An independent cohort (Vlagtwedde-Vlaardingen; n = 1,390 subjects with 8,159 FEV1 measurements during 8 surveys, table 1) was additionally studied. This cohort was prospectively followed for 25 years with FEV1 measurements (maneuver performed with a water-sealed spirometer (Lode Instruments, the Netherlands)) every 3 years (following ERS guidelines) [29].
###end p 21
###begin p 22
###xml 77 89 <span type="species:ncbi:9606">participants</span>
The study protocols were approved by local medical ethics committees and all participants gave their written informed consent.
###end p 22
###begin title 23
Selection/genotyping of Single Nucleotide Polymorphisms (SNPs)
###end title 23
###begin p 24
###xml 19 26 19 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 131 133 131 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 224 231 224 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 486 487 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 526 533 526 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
We pairwise tagged NFE2L2 and KEAP1 with respectively five and three SNPs according to the HapMap CEU genotype data (23a) with an r2 threshold of 0.8 and Minor Allele Frequency (MAF)>5%. We additionally included three novel NFE2L2 polymorphisms [22] with MAF>5%: G(-686)A (rs35652124), C(-650)A (rs6721961) and Trinucleotide CCG Repeat (TNR). SNPs were genotyped by K-Bioscience Ltd (UK) using their patent-protected competitive allele specific PCR system (KASPar). The additional file 1 contains details on SNP-selection and NFE2L2 TNR genotyping.
###end p 24
###begin title 25
Statistics
###end title 25
###begin title 26
###xml 41 42 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
SNPs in NFE2L2 and KEAP1 and level of FEV1
###end title 26
###begin p 27
###xml 196 198 196 198 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 249 251 249 251 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 452 454 452 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 532 534 532 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
We used Linear Mixed Effect (LME) to study the effects of SNPs and haplotypes (additive genetic model; coded: 0 = homozygote wild type, 1 = heterozygote, 2 = homozygote mutant) on the level of FEV1 in both cohorts separately, using all available FEV1 measurements across all surveys. This analysis was adjusted for age (defined with natural cubic spline with 4 degrees of freedom in order to take into account varying effects of age on the level of FEV1 throughout lifetime), sex, packyears smoked, height and the correlation of FEV1 measurements within each subject (random effect assigned to the intercept).
###end p 27
###begin title 28
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
SNPs in NFE2L2 and KEAP1 and course of FEV1
###end title 28
###begin p 29
###xml 46 48 46 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 135 137 135 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
We studied the effect of SNPs on course of FEV1 by introducing the interaction term of SNP x time (defined in relation to the first FEV1 measurement and with random effect assigned) into the primary analysis model described above (see additional file 1 for details).
###end p 29
###begin title 30
Analysis on the pooled cohorts
###end title 30
###begin p 31
###xml 86 88 86 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 412 418 412 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 422 429 422 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 470 471 470 471 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Finally, we pooled both cohorts, and performed analysis on the level and course of FEV1 with additional adjustment for cohort. We studied also two other models (recessive/dominant = mutant/wild type homozygotes compared to the rest genotypes) which were reported in case they showed significant effects in the pooled cohort analysis. Similarly we investigated whether there was a significant interaction between KEAP1 and NFE2L2 genotypes in relation to the level of FEV1, using two-way combinations of genetic effects with the highest statistical power i.e. dominant and additive.
###end p 31
###begin title 32
Interaction with smoking
###end title 32
###begin p 33
###xml 68 70 68 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 276 283 <span type="species:ncbi:4097">tobacco</span>
Gene by smoking interaction analysis in relation to the level of FEV1 was performed on the pooled cohorts using data from single surveys (i.e. second in the Doetinchem cohort and last in the Vlagtwedde-Vlaardingen cohort) in order to ensure the highest cumulative exposure to tobacco smoke and the highest number of subjects analyzed. The following interaction terms in two following regression models were analyzed:
###end p 33
###begin p 34
1. SNP by ever/never smoking status in the total population with adjustment for ever-smoking status and genotypes and no adjustment for packyears smoked
###end p 34
###begin p 35
2. SNP by packyears smoked within ever smokers with adjustment for packyears smoked and genotypes
###end p 35
###begin p 36
P values < 0.05 were considered to be statistically significant (tested 2-sided).
###end p 36
###begin title 37
Software
###end title 37
###begin p 38
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
LME models were run using S-PLUS (version 7.0). Linkage Disequilibrium (LD) plots and Hardy-Weinberg Equilibrium (HWE) tests were performed with Haploview (version 4.1) [30]. We identified, with a probability > 95%, subjects carrying no, one or two copies of a specific haplotype, using the *. out_pairs output file from PHASE software (version 2.1) [31,32]. We used MIX software (version 1.7) [33,34] to meta-analyze results from the Doetinchem, Vlagtwedde-Vlaardingen and British 1958 Birth cohort [35].
###end p 38
###begin title 39
Results
###end title 39
###begin title 40
###xml 21 28 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1</italic>
Genetic structure of NFE2L2 and KEAP1
###end title 40
###begin p 41
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 259 265 259 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
There was an excess of KEAP1 rs1048290 SNP heterozygotes in the Vlagtwedde-Vlaardingen cohort, which caused a significant deviation (p = 0.01) from HWE (table 2). To eliminate potential genotyping errors as underlying cause of this, we additionally genotyped KEAP1 rs9676881 SNP, that is in complete LD with rs1048290 (based on HapMap; distance between the two SNPs = 3.7 kb). This SNP also showed a significant deviation from HWE (p = 0.01; frequency of 50.6% and 12.4% for heterozygotes and homozygote mutants respectively) in the Vlagtwedde-Vlaardingen cohort.
###end p 41
###begin p 42
###xml 19 26 19 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
Characteristics of NFE2L2 and KEAP1 genotypes in the Doetinchem cohort and Vlagtwedde-Vlaardingen cohort
###end p 42
###begin p 43
SNP = Single Nucleotide Polymorphism
###end p 43
###begin p 44
HWE = Hardy Weinberg Equilibrium
###end p 44
###begin p 45
MAF = Minor Allele Frequency
###end p 45
###begin p 46
NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2
###end p 46
###begin p 47
KEAP1 = Kelch-like ECH-associated protein-1
###end p 47
###begin p 48
###xml 5 12 5 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
Five NFE2L2 TNR alleles, including three alleles not observed previously [22] i.e. 2, 6 and 7 CCG repeats, were identified in the Doetinchem cohort. These three novel alleles occurred with a total cumulative frequency of 0.4% (see additional file 1 for details).
###end p 48
###begin p 49
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 91 98 91 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 140 142 140 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 159 160 157 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 217 223 215 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2</italic>
###xml 255 261 253 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 284 285 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 306 313 304 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 410 411 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 441 447 439 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 487 488 485 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
The NFE2L2 G(-686)A (rs35652124) SNP, CCG TNR and rs2364723 SNP were in high LD as well as NFE2L2 C(-650)A (rs6721961) and rs4243387 SNPs (r2 >/= 0.96, figure 1). We observed 5 prevalent (>5% frequency) haplotypes in NFE2L2, and 4 prevalent haplotypes in KEAP1 in both cohorts (table 3). Two haplotypes in NFE2L2 (haplotypes C and D) were unique, i.e. they were not tagged by a single allele of any SNP (table 3). Similarly, 2 haplotypes in KEAP1 (haplotypes A and B) were unique (table 3).
###end p 49
###begin p 50
###xml 19 26 19 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
Characteristics of NFE2L2 and KEAP1 haplotypes occurring with >5% frequency in the two cohorts studied
###end p 50
###begin p 51
*0/1 corresponds to the major/minor allele of SNPs
###end p 51
###begin p 52
NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2
###end p 52
###begin p 53
###xml 0 43 0 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 = Kelch-like ECH-associated protein-1</italic>
KEAP1 = Kelch-like ECH-associated protein-1.
###end p 53
###begin p 54
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 0 91 0 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>NFE2L2 </italic>and <italic>KEAP1 </italic>linkage disequilibrium plots (100&#183;r<sup>2</sup>) in the Doetinchem cohort (n = 1,152)</bold>
###xml 172 179 172 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 181 258 181 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nuclear Factor Erythroid 2-Like 2 KEAP1 = Kelch-like ECH-associated protein-1</italic>
NFE2L2 and KEAP1 linkage disequilibrium plots (100.r2) in the Doetinchem cohort (n = 1,152). *given for the wild type (5 CCG repeats) and the mutant (4 CCG repeats) allele NFE2L2 = Nuclear Factor Erythroid 2-Like 2 KEAP1 = Kelch-like ECH-associated protein-1.
###end p 54
###begin title 55
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 44 45 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
NFE2L2 and KEAP1 variations and level of FEV1
###end title 55
###begin p 56
###xml 17 24 17 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 66 68 66 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 97 103 97 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 149 151 149 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
SNP rs2364723 in NFE2L2 was associated (p = 0.06) with a lower FEV1 level, and SNP rs11085735 in KEAP1 was significantly associated with a higher FEV1 level in the Vlagtwedde-Vlaardingen cohort (table 4). Similar, but non-significant trends for an additive effect were observed in the Doetinchem cohort, resulting in significant effects in the pooled cohort analysis (table 4).
###end p 56
###begin p 57
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 78 79 78 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Additive effects of genetic variations in NFE2L2 and KEAP1 on the level of FEV1
###end p 57
###begin p 58
Significant p values are depicted in bold
###end p 58
###begin p 59
* for the recessive effect: B = 76.8 ml (95% CI: 8.0-145.6), p = 0.03 (Doetinchem cohort) and B = 45.1 ml (95% CI: -15.5-105.7) p = 0.14 (Vlagtwedde-Vlaardingen cohort); p = 0.01 in the pooled cohort analysis
###end p 59
###begin p 60
###xml 82 84 82 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 172 179 172 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 183 189 183 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 236 238 236 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 402 404 402 404 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Parameter estimate B (corresponding to the "per-allele" effect on the level of FEV1 in ml), its 95% Confidence Interval and p value are estimated for genetic variations in NFE2L2 and KEAP1 using Linear Mixed Effect model analysis on FEV1 level adjusted for genotypes (coded: 0 = homozygotes wild type, 1 = heterozygotes, 2 = homozygotes mutant) packyears smoked, sex, age, height and correlation of FEV1 measurements within subjects and cohort binary variable for the pooled cohorts analysis.
###end p 60
###begin p 61
NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2
###end p 61
###begin p 62
KEAP1 = Kelch-like ECH-associated protein-1
###end p 62
###begin p 63
###xml 3 5 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
FEV1 = Forced Expiratory Volume in 1 second
###end p 63
###begin p 64
CI = Confidence Interval
###end p 64
###begin p 65
###xml 69 71 69 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
Heterozygote subjects for rs2364723 SNP had a significantly lower FEV1 level as compared to homozygote wild type subjects (figure 2), while for the rs11085735 SNP all between-genotypes differences were significant in the pooled cohort analysis (figure 3).
###end p 65
###begin p 66
###xml 17 19 17 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 81 88 81 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 0 126 0 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mean adjusted FEV<sub>1 </sub>level for heterozygote and homozygote mutant genotypes of the <italic>NFE2L2 </italic>rs2364723 SNP as compared to wild type</bold>
###xml 261 268 261 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 270 303 270 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nuclear Factor Erythroid 2-Like 2</italic>
###xml 308 310 308 310 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Mean adjusted FEV1 level for heterozygote and homozygote mutant genotypes of the NFE2L2 rs2364723 SNP as compared to wild type. Mean adjusted effects (squares) and corresponding 95% Confidence Intervals (bars) are presented. *p < 0.05 as compared to wild type. NFE2L2 = Nuclear Factor Erythroid 2-Like 2. FEV1 = Forced Expiratory Volume in 1 second.
###end p 66
###begin p 67
###xml 17 19 17 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 0 126 0 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mean adjusted FEV<sub>1 </sub>level for heterozygote and homozygote mutant genotypes of the <italic>KEAP1 </italic>rs11085735 SNP as compared to wild type</bold>
###xml 310 317 310 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224; </sup>
###xml 410 424 405 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8225; </sup>
###xml 471 514 454 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 = Kelch-like ECH-associated protein-1</italic>
###xml 519 521 502 504 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Mean adjusted FEV1 level for heterozygote and homozygote mutant genotypes of the KEAP1 rs11085735 SNP as compared to wild type. Mean adjusted effects (squares) and corresponding 95% Confidence Intervals (bars) are presented. * p < 0.05 for homozygote mutant genotype as compared to wild type or heterozygotes. dagger p < 0.05 for heterozygote genotype as compared to homozygote wild type or homozygote mutant. double dagger p < 0.05 for all between-genotype comparisons. KEAP1 = Kelch-like ECH-associated protein-1. FEV1 = Forced Expiratory Volume in 1 second
###end p 67
###begin p 68
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 52 54 52 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 153 159 153 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 189 191 189 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 255 256 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
Haplotype C in NFE2L2 was associated with higher FEV1 levels using an additive model in the pooled cohort analysis exclusively (table 4). Haplotype A in KEAP1 was associated with higher FEV1 level in a recessive model in the pooled cohort analysis (table 4). No additional consistent associations were observed for other SNPs or other genetic models (data not shown).
###end p 68
###begin title 69
Interaction between SNPs in NFE2L2 and KEAP1
###end title 69
###begin p 70
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 63 70 63 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 158 160 158 160 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
There was no significant interaction between SNPs in KEAP1 and NFE2L2 (using combinations of dominant and/or additive effects) in relation to the level of FEV1 in the pooled cohort analysis (data not shown).
###end p 70
###begin title 71
###xml 32 39 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 76 77 76 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Interaction between smoking and NFE2L2 and KEAP1 variations and level of FEV1
###end title 71
###begin p 72
###xml 91 98 91 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 138 139 138 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 173 179 173 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 267 274 267 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 318 319 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 444 450 444 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 467 471 467 471 <sub xmlns:xlink="http://www.w3.org/1999/xlink">INT </sub>
###xml 507 511 507 511 <sub xmlns:xlink="http://www.w3.org/1999/xlink">INT </sub>
###xml 545 549 545 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink">INT </sub>
###xml 585 589 585 589 <sub xmlns:xlink="http://www.w3.org/1999/xlink">INT </sub>
We observed no significant interaction between ever/never smoking status and variations in NFE2L2 or KEAP1 in relation to the level of FEV1. Yet the effect of rs11085735 in KEAP1 was significant only in never smokers, while the effect of rs2364723 and haplotype C in NFE2L2 was significant only in ever smokers (table 5). In the pooled cohort analysis we observed significant interactions between packyears smoked with two linked variations in KEAP1 i.e. rs1048290 (BINT = 1.9 ml/(packyear*allele number) SEINT = 0.9 p = 0.03) and haplotype B (BINT = 1.9 ml/(packyear*allele number) SEINT = 0.9 p = 0.04). In the single cohort analysis these interaction terms were not significant (p > 0.10 for both cohorts).
###end p 72
###begin p 73
###xml 20 27 20 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 61 63 61 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Additive effects of NFE2L2 and KEAP1 SNPs on the level of FEV1 in never- and ever-smokers
###end p 73
###begin p 74
P values depicted in bold indicate associations significant (p < 0.05) in the pooled cohort analysis within never- or ever-smokers.
###end p 74
###begin p 75
*p < 0.05 for a positive recessive effect in ever and never smokers in the pooled cohort analysis (p > 0.05 for the analysis concerning separate cohorts)
###end p 75
###begin p 76
###xml 314 320 314 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
None of the SNP in any model showed significantly different effect between never and ever smokers as tested with the pooled cohort linear regression analysis containing interaction term (binary variable reflecting smoking status) adjusted for height, sex, age, cohort and ever/never smoking status. Two underlined KEAP1 variations showed a significant interaction with packyears smoked in an additive model within ever-smokers in the pooled cohort analysis:
###end p 76
###begin p 77
###xml 12 16 12 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink">INT </sub>
###xml 56 60 56 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">INT </sub>
rs1048290: BINT = 1.9 ml/(packyear*number of alleles) SEINT = 0.9 p = 0.03
###end p 77
###begin p 78
###xml 14 18 14 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">INT </sub>
###xml 58 62 58 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">INT </sub>
Haplotype B: BINT = 1.9 ml/(packyear*number of alleles) SEINT = 0.9 p = 0.04
###end p 78
###begin title 79
###xml 8 15 8 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
SNPs in NFE2L2 and KEAP1 and course of FEV1
###end title 79
###begin p 80
###xml 53 60 53 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 93 95 93 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T6">6</xref>
We did not observe any significant effect of SNPs in NFE2L2 and/or KEAP1 on the course of FEV1 in either of the cohorts nor in the pooled cohort analysis for any genetic model tested (see table 6 for additive effects).
###end p 80
###begin p 81
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 92 93 92 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Additive effects of genetic variations in NFE2L2 and KEAP1 on the longitudinal course of FEV1
###end p 81
###begin p 82
###xml 83 85 83 85 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 176 183 176 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 187 193 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 240 242 240 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 390 392 390 392 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Parameter estimate B (corresponding to the "per-allele" effect on the change in FEV1 in ml/yr), its 95% Confidence Interval and p value are estimated for genetic variations in NFE2L2 and KEAP1 using Linear Mixed Effect model analysis on FEV1 level adjusted for genotypes (coded: 0 = homozygotes wild type, 1 = heterozygotes, 2 = homozygotes mutant), age at entry, sex, packyears smoked, FEV1 level at baseline (and their interaction with time) and correlation of lung function measurements within subjects (random factor assigned to the intercept and time) and cohort binary variable for the pooled cohorts analysis.
###end p 82
###begin p 83
NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2
###end p 83
###begin p 84
KEAP1 = Kelch-like ECH-associated protein-1
###end p 84
###begin p 85
###xml 3 5 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
FEV1 = Forced Expiratory Volume in 1 second
###end p 85
###begin p 86
CI = Confidence Interval
###end p 86
###begin title 87
Discussion
###end title 87
###begin p 88
###xml 79 86 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 104 110 104 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 133 135 133 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
The current study shows that polymorphisms in antioxidant transcription factor NFE2L2 and its repressor KEAP1 affect the level of FEV1 in the general population.
###end p 88
###begin p 89
###xml 171 188 171 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Heme Oxygenase 1 </italic>
###xml 192 218 192 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Glutamate Cysteine Ligase </italic>
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 274 281 274 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nfe2l2 </italic>
###xml 291 299 291 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 429 436 429 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 467 473 467 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 521 528 521 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 240 246 <span type="species:ncbi:10090">murine</span>
NFE2L2 is required for the transcription initiation of many antioxidant-related genes including candidate genes for lung excess function loss and COPD development such as Heme Oxygenase 1 and Glutamate Cysteine Ligase [11,27,36]. Moreover, murine models have shown that the Nfe2l2 depletion in vivo results in elastase- [17] and cigarette smoke-induced [18] emphysema development. Thus a functional genetic impairment concerning NFE2L2 and/or its cytosolic repressor KEAP1 would likely result in detrimental consequences in vivo.
###end p 89
###begin p 90
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 66 67 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 237 246 237 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SERPINA1 </italic>
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 358 381 358 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Superoxide Dismutase 3 </italic>
###xml 414 415 414 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 832 834 832 834 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1041 1043 1041 1043 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
It has been shown that lung function is genetically determined [2,3], however so far only low-prevalent polymorphisms have been consistently associated with COPD development across independent studies, i.e. the Glu342Lys substitution in SERPINA1 (frequency 1%-3% in Caucasians) that leads to a1-antitrypsin deficiency [6-8] and the Arg213Gly substitution in Superoxide Dismutase 3 (frequency 1%-2% in Caucasians) [9,10], suggesting that low-prevalent SNPs are important contributors to COPD development. Detection of the effect provided by such low prevalent SNPs often requires large sample sizes, even when the effect size is substantial. Similarly, small genetic effects for highly prevalent variations, such as those genotyped in the current study, need to be assessed in large sample sizes. Therefore, we used all available FEV1 measurements in both cohorts, in order to achieve the highest possible statistical power. Moreover, we additionally performed analyses on the pooled cohorts including over 2,500 subjects with over 11,000 FEV1 measurements.
###end p 90
###begin p 91
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 151 153 151 153 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 304 309 304 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1</italic>
###xml 430 436 430 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 466 472 466 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 502 504 502 504 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
In our opinion the most convincing association shown in the current study was that the rs11085735 SNP in KEAP1 significantly associated with higher FEV1 levels in the pooled cohort as well as in both cohorts analyzed separately, yet using different genetic models. This SNP is located in the intron 3 of KEAP1, relatively close (73 bp) to the exon 3 of this gene, and thus it might have functional consequences e.g. via affecting KEAP1 mRNA splicing. Haplotype A in KEAP1 was associated with higher FEV1 level in the Doetinchem cohort and in the pooled cohort analysis using a recessive model only. Since this haplotype does not tag any SNP that was investigated in the current study, it may be in linkage disequilibrium with another functional SNP that is either not known yet or is located outside the region that was selected for tagging.
###end p 91
###begin p 92
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 77 79 77 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 391 398 391 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 497 504 497 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
SNP rs2364723 and haplotype C in NFE2L2 were associated with the level of FEV1 in the pooled cohort analysis, as caused by a similar though not significant trends present in both cohorts. SNP rs2364723 is in almost complete LD with the recently described promoter polymorphisms i.e. G(-686)A (rs35652124) and CCG Trinucleotide repeat (figure 1) [22], implicating a role in the regulation of NFE2L2 transcription. We found no evidence for an association of another previously identified functional NFE2L2 SNP (i.e. C(-650)A (rs6721961) tagged by us with rs4243387 SNP) [23].
###end p 92
###begin p 93
###xml 99 101 99 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 161 168 161 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 254 260 254 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 356 362 356 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 449 451 449 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 553 555 553 555 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
None of the analyzed genetic variations showed a significantly different effect on the level of FEV1 between never and ever smokers, yet the effects provided by NFE2L2 rs2364723 SNP and haplotype C were more prominent in ever smokers while the effect of KEAP1 rs11085735 SNP was significant in never smokers exclusively. Interestingly another variation in KEAP1 (i.e. rs1048290 linked with haplotype B) showed a protective effect on the level on FEV1 in interaction with packyears smoked within ever smokers. The observed association of the level of FEV1 and the interaction between rs1048290 SNP and smoking can be somewhat weakened by a deviation from HWE observed for this SNP in one of the cohorts studied. Since the common cause of such deviation is a genotyping error, we have genotyped another, completely correlated, rs9676881 SNP, which also showed significant deviation from HWE. This suggests that genotyping error was not a cause of the observed deviation from HWE. Significant results obtained in the analysis stratified by smoking status (ever and never smokers), or in the gene by packyears interaction analysis did not reach significance in either of the cohorts analyzed separately. Since this could be due to insufficient power provided by single cohorts, subsequent studies are warranted.
###end p 93
###begin p 94
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 160 162 160 162 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 262 268 262 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 285 292 285 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 520 526 520 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 623 630 623 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 857 863 857 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 886 888 886 888 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 979 980 979 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 1275 1276 1275 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
Using publicly available data on the British 1958 Birth cohort [35], we checked whether our results on the significant association of SNPs with the level of FEV1 could be replicated in this independent population. The additive effects provided by. rs11085735 in KEAP1 and rs2364723 in NFE2L2 were not significant, p values being 0.11 and 0.59-0.70 (depending on the genotyping method) respectively. However, both associations were in the same direction as found in our two Dutch cohorts, i.e. positive for rs11085735 in KEAP1 (B = 52.7 ml/allele, 95% Confidence Interval (CI) = -12.6 - 118.0) and negative for rs2364723 in NFE2L2 (B = -7.3 ml/allele, 95% CI = -44.3 - 29.6, representing higher p value). A subsequent meta-analysis of the Doetinchem, Vlagtwedde-Vlaardingen and British 1958 Birth cohorts showed a higher significant protective effect of the KEAP1 SNP on the level of FEV1 (p = 0.0008) as compared to the pooled analysis in the two Dutch cohorts (p = 0.003, table 4). The p value of the additive and detrimental effect of the rs2364723 SNP was significant as well (0.036-0.046, depending on the genotyping technology in the British 1958 Birth Cohort), yet higher than the p value provided by the pooled analysis in the two Dutch cohorts (i.e. p = 0.026, table 4).
###end p 94
###begin title 95
Conclusion
###end title 95
###begin p 96
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KEAP1 </italic>
###xml 96 103 96 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 159 161 159 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 427 440 427 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2-KEAP1 </italic>
Our study performed in two independent Dutch cohorts shows that genetic variations in KEAP1 and NFE2L2 affect the level, but not the longitudinal course of FEV1 in the general population. Therefore, it remains for future considerations whether these SNPs play a role in the development or growth of the lung. Given the importance of both genes in the regulation of oxidative stress in the lung, further studies focusing on the NFE2L2-KEAP1 pathway are warranted.
###end p 96
###begin title 97
Competing interests
###end title 97
###begin p 98
MS has no conflict of interest to disclose. DSP has no conflict of interest to disclose. JMAB has no conflict of interest to disclose. GvdS has no conflict of interest to disclose. JPS has no conflict of interest to disclose. HAS has no conflict of interest to disclose. HMB has no conflict of interest to disclose.
###end p 98
###begin title 99
Authors' contributions
###end title 99
###begin p 100
MS wrote the manuscript. MS, JPS, and HMB analyzed the data. HAS and JMAB designed the Doetinchem cohort study and managed the data. JPS designed the Vlagtwedde-Vlaardingen cohort study and managed the data. GvdS participated in the genotyping process. MS, JPS, MB, JMAB, HAS, and DS interpreted the data. All authors proposed corrections and approved the final version of the manuscript.
###end p 100
###begin title 101
Supplementary Material
###end title 101
###begin title 102
Additional file 1
###end title 102
###begin p 103
###xml 0 35 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">SNP-selection and NFE2L2 genotyping</bold>
SNP-selection and NFE2L2 genotyping
###end p 103
###begin p 104
Click here for file
###end p 104
###begin title 105
Acknowledgements
###end title 105
###begin p 106
###xml 752 759 752 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFE2L2 </italic>
###xml 450 462 <span type="species:ncbi:9606">participants</span>
The authors thank the epidemiologists and fieldworkers of the Municipal Health Services in Doetinchem for their important contribution to the data collection of the Doetinchem Study as well as Jaap Seidell, Monique Verschuren, Bas Bueno-de Mesquita from the National Institute of Public Health in Bilthoven for conducting the study and Anneke Blokstra and Petra Vissink for the logistic and data management. Last but not least, the authors thank the participants of the Doetinchem and Vlagtwedde/Vlaardingen studies for their loyal participation every survey. The authors thank the staff of the genotyping unit of the Centre for Medical Biomics, particularly Elvira Oosterom, Marcel Bruinenberg and Mathieu Platteel for their help in genotyping of the NFE2L2 Trinucleotide Repeat. We acknowledge use of genotype data from the British 1958 Birth Cohort DNA collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02.
###end p 106
###begin article-title 107
From the World Health Reports 2002 and 2003 (World Health Organisation)
###end article-title 107
###begin article-title 108
Familial prevalence of chronic obstructive pulmonary disease in a matched pair study
###end article-title 108
###begin article-title 109
Genotypic and phenotypic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins
###end article-title 109
###begin article-title 110
Progress in chronic obstructive pulmonary disease genetics
###end article-title 110
###begin article-title 111
Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations
###end article-title 111
###begin article-title 112
Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group
###end article-title 112
###begin article-title 113
Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk
###end article-title 113
###begin article-title 114
###xml 22 30 <span type="species:ncbi:9606">patients</span>
Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ
###end article-title 114
###begin article-title 115
Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease
###end article-title 115
###begin article-title 116
Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function
###end article-title 116
###begin article-title 117
Association of lung function decline with the heme oxygenase-1 gene promoter microsatellite polymorphism in a general population sample. Results from the European Community Respiratory Health Survey (ECRHS), France
###end article-title 117
###begin article-title 118
###xml 18 22 <span type="species:ncbi:10090">mice</span>
Distal airways in mice exposed to cigarette smoke: Nrf2-regulated genes are increased in Clara cells
###end article-title 118
###begin article-title 119
Expression of genes involved in oxidative stress responses in airway epithelial cells of smokers with chronic obstructive pulmonary disease
###end article-title 119
###begin article-title 120
Nrf2, a multi-organ protector?
###end article-title 120
###begin article-title 121
Nrf2 defends the lung from oxidative stress
###end article-title 121
###begin article-title 122
Unique function of the Nrf2-Keap1 pathway in the inducible expression of antioxidant and detoxifying enzymes
###end article-title 122
###begin article-title 123
Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema
###end article-title 123
###begin article-title 124
###xml 15 19 <span type="species:ncbi:10090">mice</span>
Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema
###end article-title 124
###begin article-title 125
Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema
###end article-title 125
###begin article-title 126
###xml 87 95 <span type="species:ncbi:9606">Patients</span>
Downregulated NF-E2-related Factor 2 in Pulmonary Macrophages of Aged Smokers and COPD Patients
###end article-title 126
###begin article-title 127
Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1
###end article-title 127
###begin article-title 128
###xml 62 67 <span type="species:ncbi:9606">human</span>
Identification of polymorphisms in the promoter region of the human NRF2 gene
###end article-title 128
###begin article-title 129
###xml 61 67 <span type="species:ncbi:9606">humans</span>
Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury
###end article-title 129
###begin article-title 130
Epidemiology of chronic obstructive pulmonary disease
###end article-title 130
###begin article-title 131
Cohort Profile: The Doetinchem Cohort Study
###end article-title 131
###begin article-title 132
Dietary intake of antioxidant (pro)-vitamins, respiratory symptoms and pulmonary function: the MORGEN study
###end article-title 132
###begin article-title 133
Lung function loss, smoking, vitamin C intake and polymorphisms of the glutamate-cysteine ligase genes
###end article-title 133
###begin article-title 134
Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society
###end article-title 134
###begin article-title 135
A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population
###end article-title 135
###begin article-title 136
Haploview: analysis and visualization of LD and haplotype maps
###end article-title 136
###begin article-title 137
A new statistical method for haplotype reconstruction from population data
###end article-title 137
###begin article-title 138
Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation
###end article-title 138
###begin article-title 139
Development and validation of MIX: comprehensive free software for meta-analysis of causal research data
###end article-title 139
###begin article-title 140
MIX: comprehensive free software for meta-analysis of causal research data. Version 1.7
###end article-title 140
###begin article-title 141
Genetic information from the British 1958 Birth Cohort
###end article-title 141
###begin article-title 142
Heme oxygenase 1 variations and lung function decline in smokers: proof of replication
###end article-title 142

